Last week, a new Phase 3 human clinical study conducted in Turkey demonstrated that patients with mild-to-moderate COVID-19 who received the standard of care experienced a 3.5 day reduction in recovery time when receiving a nutritional protocol. The nutritional protocol included Nicotinamide Riboside “NR” (FAQs) (Reviews). These Phase 3 results follow Phase 2 data which were published in October 2020. Below are Dr Charles Brenner’s (who discovered NR as an NAD precursor vitamin) evaluation of the two studies and his opinion on the role of NR.
The following are Tweets from Dr Charles Brenner in Response to the Phase 3 Results Released in February 2021:
The following are Tweets from Dr Charles Brenner in Response to the Phase 2 Results Released in October 2020 (the last Tweet is key):
KEY QUOTE:
At the end of Dr Brenner’s final Tweet: “I expect NR (Nicotinamide Riboside) was driver of the beneficial effects in ppl”.
RELATED:
- FAQs on taking NAD boosting vitamin supplement Nicotinamide Riboside (NR) can be found HERE.
- NR supplementation may have helped sufferers of these diseases & conditions (Consumer Reviews)
Follow us on Twitter @RaisingNAD
Leave a Reply